8V8 Stock Overview
A science-based diagnostic company, develops diagnostic solutions for human microbiome market. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Genetic Analysis AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.031 |
| 52 Week High | NOK 0.12 |
| 52 Week Low | NOK 0.017 |
| Beta | 1.81 |
| 11 Month Change | -24.14% |
| 3 Month Change | -45.96% |
| 1 Year Change | -44.00% |
| 33 Year Change | -95.76% |
| 5 Year Change | n/a |
| Change since IPO | -96.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8V8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 54.0% | 1.9% | 1.5% |
| 1Y | -44.0% | -15.1% | 8.8% |
Return vs Industry: 8V8 underperformed the German Biotechs industry which returned -16.1% over the past year.
Return vs Market: 8V8 underperformed the German Market which returned 7.8% over the past year.
Price Volatility
| 8V8 volatility | |
|---|---|
| 8V8 Average Weekly Movement | 24.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8V8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8V8's weekly volatility has decreased from 45% to 24% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 21 | Ronny Hermansen | www.genetic-analysis.com |
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market. It offers GA-map Dysbiosis Test Lx, a molecular assay for profiling the gut microbiota to identify and characterize dysbiosis for treating patients with Irritable Bowel Syndrome, Inflammatory Bowel Disease, diabetes type 2, gut disorder, lifestyle diseases, and leaky-gut syndrome; GA-map COVID-19 Fecal Test Kit, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples; GA-map Dysbiosis Test reagent kit, a CE-IVD documented test, which is a software that performs QC on the run file, calculates the dysbiosis index score and abundance table, and converts sample result into reports; and GA-map Covid fecal test reagent kit, a CE-IVD documented test to detect SARS-CoV-2 in fecal samples. The company was founded in 2008 and is headquartered in Oslo, Norway.
Genetic Analysis AS Fundamentals Summary
| 8V8 fundamental statistics | |
|---|---|
| Market cap | €2.24m |
| Earnings (TTM) | -€1.76m |
| Revenue (TTM) | €1.69m |
1.3x
P/S Ratio-1.3x
P/E RatioIs 8V8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8V8 income statement (TTM) | |
|---|---|
| Revenue | NOK 19.71m |
| Cost of Revenue | NOK 3.68m |
| Gross Profit | NOK 16.03m |
| Other Expenses | NOK 36.55m |
| Earnings | -NOK 20.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 81.35% |
| Net Profit Margin | -104.06% |
| Debt/Equity Ratio | 20.5% |
How did 8V8 perform over the long term?
See historical performance and comparison